PharmTech Group

Bringing you the latest news, trends, and insight circulating the global pharmaceutical development and manufacturing industry.

[PharmTech Group @PharmTechGroup]

‼️Change is coming.
Same trusted voice.
A fresh new look.
Check back on Monday. 👀

#PharmaIndustry #BrandEvolution #PharmTech

[PharmTech Group @PharmTechGroup]

Nitrosamine analysis is evolving. Explore how LC-MS/MS and HRMS are helping analytical teams strengthen impurity detection and characterization for APIs and peptides. #MassSpectrometry
https://t.co/hT4gmT73Rv

[PharmTech Group @PharmTechGroup]

CPHI Americas 2026 is bringing together the leaders, innovators, and decision-makers who are shaping what’s next: from drug development to commercialization, supply chain resilience to manufacturing transformation.

Learn more about the show here: https://t.co/09DCHo8Nxj

[PharmTech Group @PharmTechGroup]

High-concentration biologics are testing the limits of subcutaneous delivery. Formulation, device, and fill-finish experts break down where viscosity and stability constraints actually bite, and what it takes to get patients dosing at home.

Register now: https://t.co/9a33Li22aB

[PharmTech Group @PharmTechGroup]

Inluriyo + Verzenio doubled PFS in ESR1-mutated breast cancer, 11.1 months vs. 5.5 in EMBER-3.

It's two separately made oral solid dose products, not one pill.

🔗 See the manufacturing angle: https://t.co/UstsYd2GlW

#FDA #Oncology #PharmTech

[PharmTech Group @PharmTechGroup]

Powders, granules, pellets or minitablets: your choice for a stick pack shapes taste masking, bioavailability and drug load. This webcast covers formulation strategy and how an integrated approach speeds development.

Register now: https://t.co/wDmLEgtmC5

[PharmTech Group @PharmTechGroup]

There's usually a hard threshold in high-concentration biologics where viscosity makes everything downstream harder. The decision that trips it often happens in a different discipline entirely. Join us to learn why.

Register now: https://t.co/cM3cM55Xi6

[PharmTech Group @PharmTechGroup]

AI can turn medical device risk management into a continuous signal instead of an annual review.

Under EU MDR, that shift is becoming less optional and more expected.

🔗 See how the two-layer approach works: https://t.co/eze5QsObpj

#AI #MedDevice #PharmTech

[PharmTech Group @PharmTechGroup]

Sanofi is handing 20 mature medicines & 3 manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027, freeing up capital for R&D-led growth.

Read more here👉https://t.co/nwPdyZwtvL

#Pharma #MA

[PharmTech Group @PharmTechGroup]

Stick packs are gaining ground for precision dosing and convenience-driven therapies. Learn how to get the formulation, material selection and filling strategy right, and why an integrated single-campus model can speed up development.

Register now: https://t.co/8tuiCvDQtn

[PharmTech Group @PharmTechGroup]

"Work smarter, don't skip steps."

Alfred Rumondor (AbbVie) & Swita Singh (BMS) preview their AAPS PharmSci 360 panel on the shift to formal, risk-based CMC flexibility & why cell & gene therapy no longer needs 3 PPQ batches.

Watch the preview ➡️ https://t.co/y0t9vPICTc

#CMC

[PharmTech Group @PharmTechGroup]

New modalities don't come with a playbook.

AbbVie's Alfred Rumondor, PhD, and BMS's Swita Singh, PhD, preview their AAPS PharmSci 360 panel on building CMC strategy and where AI fits in.

🔗 Watch the preview: https://t.co/m1iTCjgGxa

#AAPSPharmSci360 #CMCChallenges

[PharmTech Group @PharmTechGroup]

Why does eCOA planning need a six-month runway?

Christy Owings of Thermo Fisher on how early supply chain partnership and site visits head off costly clinical trial delays.

🔗 Watch how: https://t.co/3gIHufitAx

#eCOA #PharmTech

[PharmTech Group @PharmTechGroup]

AI isn't replacing clinical supply chain relationships. It's freeing them up.

Christy Owings of Thermo Fisher on automating shipments and spotting shifts like China's pivot to ex-China approvals in Latin America.

🔗 Watch the breakdown: https://t.co/PX2Nn9g0pc

#AI #PharmTech

[PharmTech Group @PharmTechGroup]

CPHI Milan just got a glow-up.

Four new zones landing Oct 6-8: AI & Tech, Cold Chain & Logistics, Contamination Control & Labeling.

Tara Dougal breaks down what's new here👉 https://t.co/ecTkX5iacO

#CPHIMilan2026

[PharmTech Group @PharmTechGroup]

Christy Owings, VP & GM Americas at Thermo Fisher, says vetted local partners & a solid importer of record strategy are what keep clinical trial supply chains reliable.

Just a piece of the full conversation, but for more click👇

https://t.co/Y5trf9R85x

#ClinicalTrials #Pharma

[PharmTech Group @PharmTechGroup]

The FDA just approved zilganersen, Ionis Pharmaceuticals' RNA therapy & the first disease-modifying treatment for Alexander disease.

Developers are watching its 54-patient trial as a possible blueprint for ultra-rare CNS disease.

Read more➡️ https://t.co/c4AvZggsHl

#PharmTech

[PharmTech Group @PharmTechGroup]

Clinical trial supply chains are getting more complex, and Latin America is where sponsors most underestimate the risk.

Christy Owings, VP & GM Americas at Thermo Fisher, explains why early planning matters.

Catch the rest of it here ➡️ https://t.co/jtj23AiPrN

#PharmTech

[PharmTech Group @PharmTechGroup]

Novartis just paused 8 CAR T-cell trials after 3 patient deaths.

The safety signal is specific to autoimmune and neurological patients, not oncology. Bristol Myers Squibb paused a rival program too.

🔗 See what changes for cell therapy: https://t.co/ycn7fAUB6q

#CART #PharmTech

[PharmTech Group @PharmTechGroup]

40+ years proven, now purpose-built for pharma/biotech: RFID technology for cleanroom & facility-wide asset and personnel tracking.

Learn how automated data capture improves compliance, quality, and operational efficiency.

Register now: https://t.co/M6ESIjg6Ec

[PharmTech Group @PharmTechGroup]

Novartis is paying up to $3.2B for Alteogen's ALT-B4, the fourth subcutaneous conversion deal this year. For formulators: smaller volumes, higher concentrations & autoinjector-ready fill-finish.

🔗 See what changes on the line: https://t.co/HS1CS1AtVY

#Formulation #PharmTech